GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration agreement to advance the development of T-MAXIMUM's CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents.
This collaboration between GenScript Biotech and T-MAXIMUM Biotech represents a concerted effort to leverage each other's strengths and expertise in order to expedite the development of innovative CAR-T cell therapy solutions for patients, especially those with solid tumours.
This partnership entails GenScript providing various CRISPR reagents to T-MAXIMUM Biotech, which will assist in the entire process of developing universal CAR-T products, from the initial discovery phase to eventual commercialisation.
This collaboration is expected to streamline the regulatory procedures both in China and the United States, facilitating quicker progress of T-MAXIMUM's product pipeline and subsequently benefiting patients in need at an earlier timeframe.
The focus of the collaboration is on utilising R&D-to-GMP-level sgRNA to bolster the development of UCAR-T products targeting solid tumours. While CAR-T therapies have shown promising results in treating haematological tumours, addressing the significant challenges associated with solid tumours is crucial for further advancements in the field of cell-based therapies.
